Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06359067
Status:
COMPLETED
Last Update Posted:
2024-04-11
First Post:
2024-03-25
Brief Title:
A Real-World Study of Bispecific Antibodies in Multiple Myeloma
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
A Real-World Study of Bispecific Antibodies Teclistamab and Elranatamab for Patients With Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BISPEMM
Brief Summary:
Bispecific antibody BsAb treatments teclistamab and elranatamab are newly available for patients with multiple myeloma who are refractory to all current drugs The results are very encouraging but complicated adverse events particularly infectious This study analyzes survival data in patients treated with BsAb as well as safety data in particular the proportions and locations of infectious events The results are compared to a control cohort This study is multicentric on all the university hospitals of Paris AP-HP
Detailed Description:
Bispecific antibody BsAb treatments teclistamab and elranatamab are newly available for patients with multiple myeloma who are refractory to all current drugs The results are very encouraging but complicated adverse events particularly infectious This study analyzes survival data in patients treated with BsAb as well as safety data in particular the proportions and locations of infectious events The results are compared to a control cohort This study is multicentric on all the university hospitals of Paris AP-HP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None